Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069569 | 0.86 | CTSK (0.42) | CTSKHRH3CA1CA2HSD11B1 | |
| SCHEMBL20147501 | 0.84 | CTSK (0.43) | CTSKHRH3CA1CA2HSD11B1 | |
| SCHEMBL12026411 | 0.82 | CTSK (0.59) | CTSKHRH3CA1CA2HSD11B1 | |
| SCHEMBL21779949 | 0.82 | CTSK (0.59) | CTSKHRH3CA1CA2HSD11B1 | |
| SCHEMBL14024975 | 0.82 | CTSK (0.59) | CTSKHRH3CA1CA2HSD11B1 | |
| SCHEMBL20147483 | 0.82 | CTSK (0.41) | CTSKHRH3CA1CA2HSD11B1 | |
| SCHEMBL20626705 | 0.79 | CTSK (0.40) | CTSKHRH3CA1CA2HSD11B1 | |
| SCHEMBL1456569 | 0.79 | CTSK (0.55) | CTSKHRH3CA1CA2HSD11B1 | |
| SCHEMBL25872149 | 0.78 | CTSK (0.39) | CTSKHRH3CA1CA2HSD11B1 | |
| SCHEMBL14197959 | 0.78 | CTSK (0.45) | CTSKCA1CA2HSD11B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CTSK 3569/4885HRH3 1000/4885CA1 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.